Clinical Trial

Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis

Recruiting
View on ClinicalTrials.gov →
Summary
This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria was followed/will be followed prospectively for one year. Sociodemographic characteristics, treatment adherence, perceived social support, addiction-related clinical variables, insight levels, and psychotic symptoms was assessed/will be assessed monthly using standardized psychometric instruments. The study aimed to identify predictors associated with relapse-remission patterns and changes in psychiatric symptoms over a one-year follow-up period.
Trial Details
NCT Number NCT07459257
Lead Sponsor Elazığ Mental Health and Diseases Hospital
Conditions Methamphetamine Induced Psychosis
Enrollment 150 participants
Start Date 2025-02-03
Primary Completion 2025-07-28 (estimated)
Study Completion 2026-08-17 (estimated)
Updated on ClinicalTrials.gov 2026-03-09